The funding of up to £500,000 is provided by LifeArc, a medical research charity, to support the development of Glox’s ...
A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...
MarketBeat on MSN12d
Vertex's Pain Drug: Big Pharma's Next Major Success?Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...
Irish Independent on MSN1d
Wicklow mother calls for access to life-saving therapy for son with rare form of Cystic FibrosisA Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...
CNSDespite dealing with drug-resistant infections herself since birth and being fully aware of the looming danger of running ...
Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...
Glox Therapeutics Ltd. has been awarded a share of a £3 million (US$3.7 million) collaborative discovery program launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) syndicate. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback